The U.S. National Institutes of Health (NIH) announced yesterday that a clinical trial evaluating the antiviral drug TPOXX (tecovirimat) had begun in the Democratic Republic of the Congo (DRC).
The phase 2 clinical trial evaluates TPOXX's safety and ability to mitigate monkeypox symptoms and prevent serious outcomes, including death.
Read More
